Lilly CEO David Ricks: Obesity Is a 'Silent Pandemic'—Systemic Action Is Urgently Needed

As repeated weight loss failures and cyclical weight regain have become a common plight for hundreds of millions of Chinese people, a long-overlooked truth is coming to light: obesity is not a failure of willpower, but a chronic, relapsing, and progressive disease. In 2025, the economic burden attributable to overweight and obesity in China reached RMB 1 trillion, with direct medical costs accounting for 40% and indirect economic losses—including those from reduced productivity—comprising over 60%. This represents not only a public health alarm but also a hidden concern for the nation’s economic competitiveness.

At the 2026 China Development Forum, David A. Ricks, Chairman and CEO of Eli Lilly and Company, issued a warning: obesity is evolving from an individual health issue into a major strategic challenge affecting societal sustainable development, making systemic action urgently imperative. Over the past few decades, the medical community has gradually reached a consensus that obesity is a chronic, relapsing, and progressive disease associated with more than 200 comorbidities, including diabetes, cardiovascular diseases, and various types of cancer. However, societal perception remains stuck at the level of “insufficient willpower” or “lifestyle choices,” which has directly led to delayed interventions and gaps in the healthcare system.

In the face of this “silent epidemic,” Dai Wenrui did not stop at merely highlighting the problem. He proposed three systemic recommendations: incorporating weight management as a key priority in China’s 15th Five-Year Plan, with quantifiable long-term implementation pathways; including innovative medications for obesity treatment in the National Essential Medicines List to extend evidence-based therapies to primary care settings; and leveraging basic medical insurance coverage alongside innovative payment mechanisms to clearly distinguish scientific, evidence-based weight management from aesthetic weight-loss procedures, thereby comprehensively reducing the disease burden. In his view, pharmacological intervention is not a “shortcut,” but a clinical approach equally important as lifestyle interventions—as he stated, “patients with obesity require comprehensive medical care.”

From addressing the trillion-dollar economic burden to popularizing science on obesity as a disease, and from policy recommendations to corporate practices, Dai Wenrui conveys a clear message: tackling obesity is an investment in future competitiveness. China has launched the “Year of Weight Management” initiative, demonstrating a forward-looking and systematic approach to public health. Dai Wenrui stated, “Investment in talent should begin with investment in health.” When healthy weight and a healthy economy form a positive feedback loop, a more vibrant and sustainable future society will have a solid foundation.

At the 2026 China Development Forum, David A. Ricks issued a warning: obesity is no longer merely an individual health issue, but is evolving into a major strategic challenge affecting national productivity and sustainable social development.

Eli Lilly’s newly released report, “The Cost of Inaction: A Study on the Economic Burden of Overweight and Obesity in China,” reveals this “invisible cost”: In 2025, the annual economic burden attributable to overweight and obesity in China reached RMB 1 trillion, accounting for approximately 0.7% of the country’s GDP and equivalent to the total annual fiscal subsidies for urban residents’ basic medical insurance. Of this amount, around 40% stems from direct medical expenditures, while over 60% arises from productivity losses—including absenteeism due to illness, presenteeism, and reduced labor force participation. Without systematic interventions, this figure is projected to rise to RMB 1.3 trillion by 2035, representing an increase of approximately 30%.

Meanwhile, the prevalence of overweight and obesity among Chinese adults has reached 50.7%, affecting 532 million people and ranking first globally. Obesity is associated with more than 200 comorbidities and has become the sixth leading risk factor for death in China. At the science popularization exhibition, Dai Wenrui pointed out, “Obesity is a chronic, relapsing disease.” In his forum address, he further emphasized, “Obesity is a chronic, relapsing, and progressive disease, not a personal failing. Long-term weight control through lifestyle changes alone is extremely difficult, which is why patients with obesity require comprehensive professional medical guidance.”

To dispel public misconceptions, Eli Lilly launched a weight-loss science exhibition at Wangfujing Central in Beijing on March 21. The exhibition used artistic interactive installations to illustrate the physiological mechanism of “metabolic adaptation”—the body’s physiological “resistance” that may occur when weight loss relies solely on lifestyle modifications. Dai Wenrui stated that only by helping the public understand the disease nature of obesity can we fundamentally correct the misperception that “weight loss equals cosmetic enhancement,” thereby paving the way for scientific interventions. At the exhibition, he called for adherence to scientific management, improved accessibility to effective treatments, and accelerated refinement of obesity management systems, which he noted holds promise for alleviating the long-term chronic disease management burden faced by society at its source.

In response to the increasingly severe obesity challenge, Dai Wenrui proposed three systemic solutions in his policy brief submitted to the China Development Forum, titled “From Healthy Weight to a Healthy Economy: Upgrading the Weight Management System and Enhancing Affordability to Promote Long-Term Socioeconomic Resilience.”

First, incorporate weight management as a key priority in the 15th Five-Year Plan. Dai Wenrui believes that addressing the complex societal challenges posed by obesity requires establishing long-term, quantifiable implementation pathways, strengthening cross-departmental collaborative governance, providing dedicated supporting funds, and ensuring policy implementation through result-oriented key performance indicators.

Second, expand access to evidence-based treatments. He recommended including innovative drugs for obesity treatment in the National Essential Medicines List and extending weight management services to primary healthcare systems. Dai Wenrui emphasized that pharmacological intervention is not a “shortcut,” but a clinical approach equally important as lifestyle interventions, stating, “These solutions align with the World Health Organization’s guidelines and the clinical definition of obesity.” He explicitly proposed in his recommendations: “Include innovative drugs for obesity treatment in the National Essential Medicines List and extend weight management services to primary healthcare institutions.”

Third, comprehensively reduce the disease burden through basic medical insurance coverage and innovative payment mechanisms. He recommended clearly distinguishing between evidence-based scientific weight management and medical aesthetic weight loss, promoting health technology assessment and the accumulation of cost-effectiveness evidence, gradually including innovative drugs for obesity treatment in medical insurance, and exploring diversified financing models such as employer-sponsored supplemental insurance. In his remarks, Dai Wenrui shared Eli Lilly’s practices: “At Eli Lilly, as an employer, we have covered obesity management medications for our employees—not only in China but also in many countries globally. We believe this approach can serve as a model for societal risk-sharing.”

At the thematic seminar on “Healthy China 2030” and the development of the broader health industry, Dai Wenrui stated, “Investment in talent should begin with investment in health. However, the increasingly severe challenge of obesity is becoming a significant obstacle to achieving this goal. Obesity is not merely a health issue; it also bears on national development, productivity enhancement, and future competitiveness.” He pointed out that China’s launch of the “Year of Weight Management” initiative fully demonstrates the government’s forward-looking and systematic approach to public health. By promoting earlier intervention and improving access to innovative treatments, this initiative holds promise for jointly building a healthier and more vibrant society for the future.

Dai Wenrui particularly emphasized that the above recommendations are highly aligned with the “Healthy China 2030” strategy. “Delaying responses to the obesity challenge will impose escalating health and economic burdens on individuals, families, and society as a whole. By adhering to scientific management, improving access to effective treatments, and accelerating the improvement of obesity management systems, we can hopefully alleviate the long-term pressure of chronic disease management at its source. Eli Lilly is committed to working with diverse partners to drive progress through innovation and collaboration, benefiting more patients in China.”